Particle.news
Download on the App Store

Large ADHD Trial Finds No Benefit From FDA-Cleared Trigeminal Stimulation Device

Robust blinding undercuts the pilot evidence behind the device’s FDA clearance.

Overview

  • The peer-reviewed Nature Medicine study randomized 150 UK youths aged 8–18 to active or sham external trigeminal nerve stimulation for four weeks with overnight use.
  • An intermittent, hourly pulse sham preserved masking, and both groups showed similar improvement on the primary ADHD Rating Scale with no significant between-group difference.
  • Most secondary and physiological measures, including sleep, anxiety, activity trackers, and pupil arousal, showed no advantage for active stimulation.
  • An isolated signal of greater reduction in self-reported mind-wandering emerged with active treatment, which authors said does not support broad clinical use.
  • Safety and adherence were strong, yet investigators said the null results challenge the 2019 FDA clearance based on a 62-participant pilot that lacked an active-mimicking control and may warrant regulatory and guideline reassessment.